In conclusion, anti-TNF agents are an established option for the

In conclusion, anti-TNF agents are an established option for the treatment of psoriasis, but the safety

profile should be carefully monitored. Even otherwise healthy patients with no predisposing factors for TB should be cautiously managed during biologic therapy. It is mandatory for the dermatologists who prescribe anti-TNF agents to carefully evaluate the 3-Methyladenine mouse patients to exclude concomitant TB and non-TB infections. Continuous vigilance, long-term follow-up, and systematic reporting of any suspected association between SB-715992 cell line active TB and biologic therapy will improve the prevention and management of this complication. Acknowledgments This work was not supported financially or otherwise. Dr. Chiticariu is the guarantor for this article, and takes responsibility for the integrity of the work as a whole. Conflict of selleck chemical interest Dr. Solovan has no conflict of interest to disclose. Dr. Chiticariu has no conflict

of interest to disclose. Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. References 1. Parisi R, Symmons DP, Griffiths CE, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133:377–85.PubMedCrossRef 2. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and PAK6 guidelines

of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58:826–50.PubMedCrossRef 3. Tubach F, Salmon-Céron D, Ravaud P, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum. 2009;60:1884–99.PubMedCrossRef 4. Global tuberculosis report 2012, World Health Organization, 2012. http://​www.​who.​int/​tb/​publications/​global_​report/​en/​. Accessed Jan 28, 2013. 5. Sánchez-Moya AI, Dauden E. Incidence of tuberculosis infection in psoriatic patients on anti-TNF therapy: report of a case series with 144 patients. J Eur Acad Dermatol Venereol. 2011;25:730–3.PubMedCrossRef 6. Denkinger CM, Dheda K, Pai M. Guidelines on interferon-γ release assays for tuberculosis infection: concordance, discordance or confusion? Clin Microbiol Infect. 2011;17:806–14.PubMedCrossRef 7. Doherty SD, Van Voorhees A, Lebwohl MG, et al. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. J Am Acad Dermatol. 2008;59:209–17.PubMedCrossRef 8. Brown AJ, Lesher JL Jr.

Comments are closed.